Travis Steed
Stock Analyst at B of A Securities
(2.67)
# 1,697
Out of 5,182 analysts
94
Total ratings
43.84%
Success rate
5.76%
Average return
Main Sectors:
Stocks Rated by Travis Steed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Maintains: Buy | $150 → $120 | $92.80 | +29.31% | 6 | Apr 17, 2026 | |
| MMED MiniMed Group | Initiates: Buy | $27 | $12.92 | +108.98% | 1 | Mar 31, 2026 | |
| TNDM Tandem Diabetes Care | Upgrades: Neutral | $15 → $30 | $19.82 | +51.36% | 3 | Feb 20, 2026 | |
| BBNX Beta Bionics | Maintains: Buy | $30 → $33 | $10.65 | +209.86% | 1 | Jan 5, 2026 | |
| PEN Penumbra | Maintains: Buy | $320 → $370 | $327.98 | +12.81% | 2 | Jan 5, 2026 | |
| BDX Becton, Dickinson and Company | Maintains: Neutral | $190 → $207 | $150.22 | +37.80% | 10 | Jan 5, 2026 | |
| CNMD CONMED | Maintains: Neutral | $65 → $52 | $37.87 | +37.31% | 5 | Dec 8, 2025 | |
| MASI Masimo | Initiates: Neutral | $162 | $178.66 | -9.32% | 1 | Nov 17, 2025 | |
| SOLV Solventum | Maintains: Neutral | $80 → $85 | $69.78 | +21.81% | 3 | Feb 26, 2025 | |
| EW Edwards Lifesciences | Upgrades: Buy | $82 → $90 | $83.46 | +7.84% | 4 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $21.14 | +51.37% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $42 → $45 | $18.49 | +143.37% | 5 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $480 → $45 | $4.41 | +920.41% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $315 | $329.01 | -4.26% | 5 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $365 → $295 | $188.31 | +56.66% | 3 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $39.39 | -59.38% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 → $160 | $92.59 | +72.80% | 11 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $315 | $470.99 | -33.12% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $8 | $1.28 | +525.00% | 1 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $25 | $9.24 | +170.56% | 1 | Jun 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $85 | $14.31 | +493.99% | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $61.41 | +103.55% | 7 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $145 | $82.92 | +74.87% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $51 | $59.95 | -14.93% | 9 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $59 → $54 | $10.69 | +405.15% | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $84.11 | -73.84% | 1 | Jul 17, 2017 |
Abbott Laboratories
Apr 17, 2026
Maintains: Buy
Price Target: $150 → $120
Current: $92.80
Upside: +29.31%
MiniMed Group
Mar 31, 2026
Initiates: Buy
Price Target: $27
Current: $12.92
Upside: +108.98%
Tandem Diabetes Care
Feb 20, 2026
Upgrades: Neutral
Price Target: $15 → $30
Current: $19.82
Upside: +51.36%
Beta Bionics
Jan 5, 2026
Maintains: Buy
Price Target: $30 → $33
Current: $10.65
Upside: +209.86%
Penumbra
Jan 5, 2026
Maintains: Buy
Price Target: $320 → $370
Current: $327.98
Upside: +12.81%
Becton, Dickinson and Company
Jan 5, 2026
Maintains: Neutral
Price Target: $190 → $207
Current: $150.22
Upside: +37.80%
CONMED
Dec 8, 2025
Maintains: Neutral
Price Target: $65 → $52
Current: $37.87
Upside: +37.31%
Masimo
Nov 17, 2025
Initiates: Neutral
Price Target: $162
Current: $178.66
Upside: -9.32%
Solventum
Feb 26, 2025
Maintains: Neutral
Price Target: $80 → $85
Current: $69.78
Upside: +21.81%
Edwards Lifesciences
Dec 16, 2024
Upgrades: Buy
Price Target: $82 → $90
Current: $83.46
Upside: +7.84%
Nov 5, 2024
Initiates: Buy
Price Target: $32
Current: $21.14
Upside: +51.37%
Mar 5, 2024
Maintains: Neutral
Price Target: $42 → $45
Current: $18.49
Upside: +143.37%
Oct 13, 2023
Downgrades: Underperform
Price Target: $480 → $45
Current: $4.41
Upside: +920.41%
Sep 5, 2023
Upgrades: Buy
Price Target: $315
Current: $329.01
Upside: -4.26%
Aug 24, 2023
Maintains: Buy
Price Target: $365 → $295
Current: $188.31
Upside: +56.66%
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $39.39
Upside: -59.38%
May 3, 2023
Upgrades: Neutral
Price Target: $120 → $160
Current: $92.59
Upside: +72.80%
Apr 19, 2023
Maintains: Buy
Price Target: $300 → $315
Current: $470.99
Upside: -33.12%
Jan 3, 2023
Downgrades: Underperform
Price Target: $8
Current: $1.28
Upside: +525.00%
Jun 21, 2022
Initiates: Underperform
Price Target: $25
Current: $9.24
Upside: +170.56%
Oct 13, 2021
Maintains: Overweight
Price Target: $120 → $85
Current: $14.31
Upside: +493.99%
May 25, 2021
Initiates: Overweight
Price Target: $125
Current: $61.41
Upside: +103.55%
May 25, 2021
Initiates: Equal-Weight
Price Target: $145
Current: $82.92
Upside: +74.87%
May 25, 2021
Initiates: Overweight
Price Target: $51
Current: $59.95
Upside: -14.93%
Nov 1, 2018
Maintains: Neutral
Price Target: $59 → $54
Current: $10.69
Upside: +405.15%
Jul 17, 2017
Initiates: Overweight
Price Target: $22
Current: $84.11
Upside: -73.84%